# High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

> **NCT00002948** · PHASE1 · TERMINATED · sponsor: **Yale University**

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** topotecan hydrochloride
- **PROCEDURE:** bone marrow ablation with stem cell support
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00002948
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-10
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** — (—)
- **Last updated:** 2014-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002948, "High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00002948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*